According to AIIMS director Dr Guleria, results of the Covaxin trials on children can be expected in September. Trials of Bharat Biotech’s Covaxin on children are currently underway, with the second dose of the Covid-19 vaccine likely to be administered to children aged 2-6 years next week. Also Read Bharat Biotech terminates MoU with Brazilian partners amid corruption allegations […]
New Delhi [India], July 23 (ANI): Bharat Biotech on Friday said it has terminated agreements it had signed with two Brazilian companies - Precisa Medicamentos and Envixia Pharmaceuticals LLC to introduce its Covid-19 Covaxin in Brazil.
New Delhi [India], July 23 (ANI): As part of its COVID-19 vaccination trials for children, Bharat Biotech is likely to administer the second dose of Covaxin to children aged between 2 and 6 years next week, sources said on Thursday.
New Delhi [India], July 19 (ANI): Officials of the World Health Organisation (WHO) had a meeting with those of Bharat Biotech and the Hyderabad-based vaccine maker's dossier for Emergency Use Listing (EUL) of Covaxin is under review by the technical experts for consideration, Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said on Monday.
Hyderabad (Telangana) [India], July 12 (ANI): With a review process of 'Covaxin', the indigenous vaccine against COVID-19 commencing at the World Health Organisation (WHO), the Hyderabad-based Bharat Biotech on Monday said it expects to receive emergency use listing (EUL) from the global body at the earliest.
Geneva [Switzerland], July 10 (ANI): The World Health Organisation (WHO) is likely to take a decision on Emergency Use Listing (EUL) of Bharat Biotech's Covaxin and announce it in the first week of August.
Buenos Aires [Argentina], July 3 (ANI/Sputnik): The Supreme Federal Court of Brazil has approved a probe into President Jair Bolsonaro regarding alleged overpricing during the purchase of India's coronavirus vaccine Covaxin, the G1 website reported.
New Delhi [India], (ANI): Hours after Bharat Biotech announced that its vaccine Covaxin's efficacy against COVID-19 is 77.8 per cent, National Technical Advisory Group on Immunisation (NTAGI) Chief Dr NK Arora said that these results will help the vaccine get recognition from the World Health Organisation (WHO).